Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.
Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.
Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.
Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).
Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.
Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.
Dr. Andrew Lane discusses CD123-targeted therapies, particularly the antibody-drug conjugate pivekimab sunirine (PVEK), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He notes PVEK's promising response rates and safety profile from early trial data, including lower risk of concerning side effects like capillary leak syndrome that can occur with the currently approved CD123-targeting agent tagraxofusp. In closing, he emphasizes accurately diagnosing BPDCN via expert hematopathology review and referral to specialized centers taking a cross-disciplinary approach, as combining emerging CD123-directed therapies with stem cell transplant as appropriate gives the best chance for optimal BPDCN management.
Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.
Andrew Brenner, MD, PhD, discusses how liposomal encapsulation of radiotherapeutics holds significant promise as a treatment of glioblastoma.
Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Clinical trials demand extreme rigor. A mistake in trial design, like a bookkeeping error, can lead regulators to reject a potentially valuable drug. Many researchers dislike this intense focus on dotting i’s and crossing t’s. Omid Hamid, MD, enjoys the challenge.
Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.
Andrew Dannenberg, MD, professor of Medicine, Weill Cornell Medical College, discusses the association between breast inflammation and breast cancer risk.
Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the future treatment landscape for patients with neuroendocrine tumors (NETs).
Over the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.
Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).
Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.
Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.
Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.
Andrew Jennis, MD a hematologist/oncologist at Hackensack Meridian Health, who specializes in the diagnosis and treatment of digestive cancers, discusses the Centers for Medicare & Medicaid Services’ Oncology Care Model, a value model in which there is the opportunity for shared savings for both oncologists and CMS, so long as oncology care is administered in a cost-efficient manner.
Although development outlays with proton therapy have decreased, treatment costs remain higher than for conventional radiotherapy, fueling a debate about whether the benefits justify the costs.